Resistance to tamoxifen is observed in half of the recurrences in breast cancer, where the anti-estrogen tamoxifen acquires agonistic properties for transactivating estrogen receptor a (ERa). In a previous study, we showed that protein kinase A (PKA)-mediated phosphorylation of serine 305 (S305) of ERa results in resistance to tamoxifen. Now, we demonstrate that phosphorylation of S305 in ERa by PKA leads to an altered orientation between ERa and its coactivator SRC-1, which renders the transcription complex active in the presence of tamoxifen. This altered orientation involves the C-termini of ERa and SRC-1, which required a prolonged AF-1-mediated interaction. This intermolecular reorientation as a result of PKAmediated phosphorylation of ERa-S305 and tamoxifen binding provides a unique model for resistance to the anticancer drug tamoxifen.
Introduction
Tamoxifen is a highly effective anticancer drug in estrogen receptor a (ERa)-positive breast cancer patients. In recurrent disease however, still half of the patients develop resistance, where tamoxifen acquires agonistic properties for transactivation of ERa. Various mechanisms may account for insensitivity to tamoxifen, including activation of the mitogenactivated protein kinase (MAPK), protein kinase A (PKA) and p21-activated kinase-1 (PAK-1) signaling pathways that show enhanced activity in tamoxifen-resistant breast tumors (Michalides et al, 2004; Gutierrez et al, 2005; Holm et al, 2006) . These kinases may directly target ERa. However, the molecular details of how these events contribute to tamoxifen resistance remain elusive. Antagonists of ERa act by altering the orientation of the C-terminally located a-helix 12 of the ligand binding domain (LBD) of ER (Brzozowski et al, 1997) . In the agonist-bound state, cofactors bind to the pocket composed of helices 3, 4, 5 and 12 (Pike, 2006) . Anti-estrogens induce a distortion in a-helix 12 covering this binding pocket, thereby preventing the association with the p160 family of coactivators (Shiau et al, 1998) . These cofactors are essential to initiate transcription (Kamei et al, 1996) and include SRC-1 (or NcoA-1), SRC-2 (also known as TIF-2, GRIP1 or NcoA-2) and SRC-3 (also known as RAC3, ACTR, AIB1, P/CIP or TRAM) (Xu and Li, 2003) . SRC-1 can interact with CREB binding protein (CBP), as well as with both the N-terminal AF-1 and the C-terminal AF-2 domains of ERa (Metivier et al, 2001 ). The AF-1 and AF-2 domains cooperate in transactivation of ERa (Metivier et al, 2002; Dutertre and Smith, 2003) . Activity of SRC-1 is modified by phosphorylation at multiple sites, two of which are attributed to PKA activation (Rowan et al, 2000a) . The SRCs can have different cellular properties: while SRC-1 and SRC-3 can be recruited to unliganded ERa, SRC-3 is more readily displaced from ERa in the presence of antagonists as compared to SRC-1 (Sharp et al, 2006) . Overexpression of SRC-1 and SRC-3 is correlated with tamoxifen resistance in breast cancer patients (Osborne et al, 2003; Myers et al, 2004) . Moreover, agonistic activity of tamoxifen is enhanced by overexpression of SRC-1 in normal uterus tissue (Shang and Brown, 2002) .
Previously we reported that tamoxifen resistance mediated by PKA is caused by phosphorylation of serine 305 (S305) of ERa (Michalides et al, 2004) . Recently, S305 of ERa was also reported to be the target of PAK-1 (Wang et al, 2002) , and its overexpression correlates with resistance to tamoxifen in breast cancer patients (Holm et al, 2006) . These findings identify S305 as a crucial site in ERa that upon phosphorylation by either PKA or PAK-1 is responsible for resistance to tamoxifen. This phosphorylation switches tamoxifen from an antagonist to an agonist of ERa, and affects conformational changes in ERa following binding to tamoxifen and other anti-estrogens (Michalides et al, 2004; Zwart et al, 2007) . The mechanistic details of this process are, however, still unclear. Here, we report that PKA-mediated phosphorylation of ERa alters the orientation between ERa and coactivator SRC-1, without affecting the overall binding between ERa and SRC-1 in tamoxifen-treated cells. We applied fluorescent resonance energy transfer (FRET) in living cells to visualize changes in orientation between ERa and SRC-1 following tamoxifen binding, which was dependent on phosphorylation of the PKA target S305 in ERa. This affected the recruitment of RNA polymerase II and led to ER-mediated transcription in cells treated with tamoxifen. In summary, tamoxifen resistance via PKA or PAK-1 occurs through phosphorylation of S305 in ERa, which alters its orientation towards coactivator SRC-1 and recruitment of RNA polymerase II, thereby stimulating ER-driven transcription by the anti-estrogen tamoxifen.
Results

PKA phosphorylates ERa-S305
To follow the immediate interactions between ERa and its cofactor SRC-1 in cells transfected with tagged ERa and SRC-1 constructs, U2OS cells were used as a model cell line, since they are easily transfectable. However, the same results were also obtained in HeLa cells and in breast cancer cells T47D and MCF7 (Michalides et al, 2004; this study) . To show that S305 is indeed phosphorylated by PKA, U2OS cells transfected with ERa were treated with 8-Br-cAMP, to activate PKA. This resulted in a specific phosphorylation of ERa-S305 ( Figure 1A ). The mutant ERa S305A , where the S305 was replaced with an alanine to prevent phosphorylation of that site by PKA, was not detected with the ERa-S305-specific antibody. The ERa-S305 phosphate-specific antibody did not detect the putative phosphomimics of ERa-S305, ERa S305E or ERa S305D , where S305 was replaced with glutamate or aspartate, respectively. We therefore preferred wild-type ERa treated with PKA activators 8-Br-cAMP or forskolin, with ERa S305A as a control. The concentration of (anti)-estrogens used in the study was similar to those in the previous study (Michalides et al, 2004) , and were optimally effective for the levels of ERa expressed in the cells. Figure 1 Binding between ERa and SRC-1 is not affected by PKA activation. (A) Characterization of S305-ERa as PKA target. U2OS cells were transfected with the wild-type YFP-ERa-CFP construct or the S305A mutant thereof, cultured in the presence or absence of 8-Br-cAMP and analyzed for S305 phosphorylation of wild-type ERa or the phospho-mutant of ERa. Anti-tubulin staining was used as a loading control, anti-GFP as an expression control. Absence of the phosphorylated S305-ERa protein in the cells transfected with S305A, but its presence in the PKAtreated cells transfected with wild-type indicates the inability to phosphorylate mutant ERa S305A by PKA. (B) M2H analysis of ERa/SRC-1 interactions. U2OS cells transfected with DBD-SRC-1 (623-711 or full length), TA-ERa (wt or S305A), GAL4-luciferase and Renilla luciferase DNA were cultured in medium containing CTS only, or in the presence of 1 mM Estradiol (E2), 1 mM ICI 182,780 or 1 mM 4 0 OH-tamoxifen for 96 h. Twenty-four hours before analysis 100 mM 8-Br-cAMP was added, where indicated. Luciferase activity was measured and related to ICI 182,780 values without cAMP, for every transfectant, and set to 1. Bars indicate standard deviations from three independent experiments. (C) FRAP analysis of ERa/SRC-1 interactions. U2OS cells were transfected with SRC-1 623À711 -YFP (left panel) or SRC-1 FL -YFP (middle panel), and ERa-CFP, MCF7 cells were transfected with SRC-1 FL -YFP only (right panel). These were cultured in CTS containing medium, and 1 mM Estradiol (E2) or 1 mM 4 0 OH-tamoxifen was added 15 min before analysis, where indicated. Cells were pretreated with 10 mM forskolin for 15 min, where indicated. YFP was bleached and fluorescence intensities were followed in time in the bleach spot from which t 1/2 (half-time to recovery) was calculated as described in Materials and methods. Bars indicate standard deviations from 410 cells per condition. Student t-test was performed for each bar, compared to SRC-1 623À711 -YFP or SRC-1 FL -YFP expression alone. *Po0.05.
Phosphorylation of ERa-S305 by PKA does not influence overall binding to SRC-1 Since ligand-induced activation of ERa is generally followed by binding to a coactivator, we hypothesized that insensitivity to tamoxifen by PKA-mediated phosphorylation of S305 would affect the binding between ERa and cofactor SRC-1. This was first investigated in a mammalian two-hybrid (M2H) assay. To distinguish between the interaction of SRC-1 with AF-1 and/or AF-2 domains of ERa, the SRC-1 truncation mutant, aa 623-711 (SRC-1 623À711 ) was used that only binds to the ligand binding AF-2 domain of ERa, as described previously (Llopis et al, 2000) , as well as the full-length SRC-1 (SRC-1 FL ), which interacts with both AF-1 and AF-2 domains of ERa (Metivier et al, 2001) . Expression of the fusion proteins was confirmed by Western blotting (Supplementary Figure S1) . Chimeras of ERa and the transactivation domain of GAL4 (TA-ERa), as well as SRC-1 623À711 or SRC-1 FL fused to the DNA binding domain of GAL4 (DBD-SRC-1), were cotransfected with a GAL4-responsive luciferase expression construct and Renilla luciferase construct as a transfection control ( Figure 1B ). In this assay, luciferase activity is directly related to the binding between the two fusion proteins. SRC-1 623À711 interacted with ERa in the presence of E2 and this was only slightly increased by preincubation of the cells with PKA activator 8-Br-cAMP ( Figure 1B , left panel). No binding was observed under tamoxifen and ICI 182,780 conditions, also not in the presence of 8-Br-cAMP. The binding of full-length SRC-1 was increased by E2 and, surprisingly, also by the partial antagonist tamoxifen ( Figure 1B , right panel). Treatment with the full ERa antagonist ICI 182,780 resulted in a loss of binding. ICI 182,780 not only inhibits ERa activity but also induces degradation of ERa, and defined the inactive state of ERa in our measurements. The interaction between ERa and SRC-1 FL was not influenced by 8-Br-cAMP under all tested conditions. These results indicated that PKA activation does not affect the overall binding between ERa and SRC-1. In addition, whereas binding of SRC-1 to the AF-2 domain of ERa is induced by E2 and was abrogated by tamoxifen (Llopis et al, 2000) , binding of SRC-1 to the AF-1 domain of ERa prevailed under hormone-depleted conditions and in the presence of tamoxifen, as was reported previously (Metivier et al, 2001) .
In order to verify the M2H results in living cells and in a dynamic context, we visualized interactions between ERa and SRC-1 using fluorescence recovery after photobleaching (FRAP) in U2OS cells. In FRAP, fluorophores in the region of interest are bleached using a high-intensity laser beam and recurrence of fluorescence is followed in time, as described before (Stenoien et al, 2001) , and illustrated in Supplementary Figure S2 . The mobility of the fluorophoretagged protein of interest, whether alone or in (transient) complex with interaction partners, can be monitored in this way. The statistics of the t 1/2 recovery values are given in Figure 1C . SRC-1 623À711 interacts with the AF-2 domain of ERa. Upon expressing SRC-1 623À711 in the absence of ERa, the t 1/2 value was low (indicating rapid diffusion in the nuclear compartments) and was not changed after addition of E2 or tamoxifen (data not shown). When SRC-1 623À711 was coexpressed with ERa, introduction of the hormone E2 decreased the mobility of SRC-1 623À711 , suggesting interactions with ERa following binding to E2. The mobility of SRC-1 623À711 under conditions of charcoal-treated serum (CTS) was slower than in the presence of tamoxifen, and was not affected by treatment with forskolin that activates PKA. The t 1/2 recovery values for SRC-1 FL indicated increased interactions between ERa and SRC-1 FL under conditions of CTS, E2 and tamoxifen as well, since they were higher than the t 1/2 recovery value of SRC-1 FL -YFP alone ( Figure 1C , middle column). The latter was not affected by E2 or tamoxifen (data not shown). The mobility of SRC-1 FL -YFP in breast cancer MCF7 cells showed a similar pattern as was obtained in U2OS cells cotransfected with exogenous ERa ( Figure 1C , right column), indicating that the FRAP results are not cell type specific and are in U2OS cells with exogenous ERa comparable to the breast cancer MCF7 cells with an endogenous ERa only.
The combined results of the M2H and FRAP experiments indicated that SRC-1 FL can interact with ERa in hormonedepleted (CTS) as well as in E2 and tamoxifen-treated cells. They strongly suggested that the AF-1 domain of ERa is involved in binding under all three conditions, whereas the AF-2 domain is participating in binding only in the presence of E2. Importantly, PKA activation, which is known to induce tamoxifen resistance, did not influence the interaction between SRC-1 and ERa.
Phosphorylation of S305 by PKA alters the orientation between ERa and SRC-1 under tamoxifen conditions
If binding is not affected by PKA-mediated phosphorylation of ERa-S305, does this phosphorylation have an effect on the mode of interaction between ERa and SRC-1? We investigated this by FRET technology using confocal imaging in HeLa cells. FRET is the radiationless energy transfer from one fluorophore to the next, and occurs when two dipole moments of overlapping fluorophores couple within a distance of B80 Å . Intermolecular FRET thereby provides a most direct method to study interactions between two proteins, and is strictly dependent on the distance between the fluorophores as well as their relative orientations, allowing visualization of conformational changes within protein-protein complexes. In these experiments and in the FRAP experiments described above, we used cells with a 2-to 3-fold expression of exogenous ERa-CFP as compared to endogenous ERa expression in MCF7 cells ( Figure 2A ). FRET was detected between ERa-CFP and SRC-1 623À711 -YFP ( Figure 2B) ; here, excitation of CFP at 430 nm yielded emission of YFP that, after correction of leak-through, only could have arisen from FRET (lower left panel). The observed FRET signal was normalized for the amount of CFP emission as is described in Materials and methods, yielding the corrected donor FRET efficiency (E D ) that is presented in the lower right panel. E D represents the FRET per donor-acceptor fluorophore pair, and is independent of donor fluorescence. Under hormonedepleted conditions, a high E D was observed for ERa-CFP and SRC-1 623À711 -YFP, which was strongly reduced by tamoxifen ( Figure 2B ), indicating that the interaction in CTS between ERa and SRC-1 623À711 was altered by tamoxifen. When FRET efficiency was quantified by determining the E D per pixel, as described in Materials and methods, we observed that the average efficiency of 16% FRET between ERa-CFP and SRC-1 623À711 -YFP under hormone-depleted conditions was reduced to an average of 5% after addition of tamoxifen to this particular cell ( Figure 2D ) and others ( Figure 2E ). Note that the spread in pixel E D values is due to contribution of noise. PKA activation by forskolin under conditions of CTS did not significantly influence FRET efficiency between ERa and SRC-1 623À711 ( Figure 2C , and quantified in Figure 2E ). Subsequent treatment with tamoxifen still led to a substantial reduction in FRET efficiency. This indicated that PKA activation did not influence the binding between the AF-2 domain of ERa and SRC-1 623À711 -YFP, which agrees with the results obtained by FRAP and M2H ( Figure 1 ).
We next investigated whether PKA treatment had any effect on the orientation between full-length SRC-1 and ERa using FRET (Figure 3) . FRET between ERa and SRC-1 FL was less efficient as with SRC-1 623À711 , which may be attributed to the much larger protein size of the full-length SRC-1 and hence the larger distance between the fluorophores at the ends of the tagged proteins, but may also be the result of different orientation of the fluorophores. FRET between ERa-CFP and SRC-1 FL -YFP was detected in hormone-deprived cells and was reduced by tamoxifen ( Figure 3A) , supporting the FRAP experiments, where these proteins could be found to interact under hormone-deprived conditions. The mean FRET efficiency of 9% in CTS was reduced to 3% when tamoxifen was added ( Figure 3C ). This is remarkable, since the M2H and FRAP experiments demonstrated that the interaction between ERa and SRC-1 FL was not affected by tamoxifen (Figure 1 ). This suggested that a loss of FRET under conditions of tamoxifen indicated an altered orientation between ERa and SRC-1, where the C-termini of ERa and SRC-1 FL that carry the fluorophores position differently in tamoxifen-treated cells than under CTS conditions. We next investigated whether activation of PKA influenced this reorientation upon tamoxifen binding. PKA activation through forskolin had no effect on FRET efficiency under hormone-deprived conditions ( Figure 3B ). However, subsequent treatment with tamoxifen did not show alterations in FRET efficiency analogous to cells not pretreated with forskolin, indicating that the orientation between ERa and SRC-1 FL is stabilized by activation of PKA. The ERa S305A mutant behaved similar as wild-type ERa under non-PKA stimulated conditions: forskolin treatment followed by tamoxifen still resulted in a loss of FRET ( Figure 3D , right panel and Supplementary Figure S3 ). This indicates that phosphorylation of wild-type ERa S305 by PKA affects the orientation between ERa and full-length SRC-1 (quantified in Figure 3D and E). These data were verified in U2OS (not shown) and MCF7 cells (Supplementary Figure S4D-F) , indicating that the results of these FRET experiments were cell type independent. These results were further confirmed by fluorescence lifetime imaging microscopy (FLIM), which is an alternative FRET approach (Zwart et al, 2005) (Supplementary Figure S4A-C) . Taken together, these data showed that the orientation between ERa-CFP and SRC-1 FL -YFP is altered by tamoxifen, unless PKA phosphorylates S305 in ERa.
ERa interacts in the nucleus with SRC-1 irrespective of DNA promoter content
Given the limits of resolution of the light microscope and the relatively low number of specific estrogen response elements (ERE) in the genome (Carroll et al, 2006) , it is not possible to directly relate high FRET efficiency between ERa and SRC-1 to ERE binding (Figures 3 and 4) . Since the transcription function of ERa can be mediated by direct interaction with EREs at the promoters of target genes, we determined FRET signals in HeLa cells that contain a multicopy prolactin promoter/ enhancer (PRL) DNA array containing natural ERa binding sites. Transcription from this visible locus is regulated by ligand-bound ER, and ERa and recruited cofactors can be readily identified (Sharp et al, 2006) . This permitted a clear distinction between defined ERE-associated ERa and SRC-1 Figure 2 Orientation between ERa and SRC-1 623À711 is altered in the presence of tamoxifen and is independent of phosphorylation of S305 of ERa by PKA. (A) Expression levels of ERa-CFP related to endogenous expression. MCF7 cells were transfected with ERa-CFP, fixed and stained for ERa. Cells with CFP-positive nuclei were compared to exclusively endogenous ERa expressing cells. FRET measurements were performed on PRL array containing HeLa cells, transfected with ERa wt -CFP and SRC-1 623À711 -YFP. (B, C) FRET images were generated from cells cultured in hormone-depleted (CTS) medium only (B and C, left panels) or after treatment with 10 mM forskolin before FRET measurements (C, middle panel). Subsequently, 1 mM 4 0 OH-tamoxifen (TAM) was added and after 15 min cells were imaged (B and C, right panels). FRET and donor FRET efficiency (E D ) were calculated as described in Materials and methods. For each condition described in panels B and C, the raw E D values from the whole nucleus were related to the total amount of pixels. (D) Mean E D is indicated and quantifications (E) are performed on 410 independent measurements, where the E D under CTS conditions is set to 1 for each experiment (relative E D ). Bars indicate standard deviations. Bars at the right indicate relative intesity. Figure 3A and B (indicated by arrowheads). Here, we compared the FRET efficiency on the PRL array with that throughout the remainder of the nucleus ( Figure 3E ). The levels of ERa-CFP, SRC-1-YFP proteins and FRET events were significantly higher on the PRL array than outside, as shown in Figure 3A and B. However, when FRET from these cells was related to the emission of the donor (E D ) to render the readout fluorophore concentration independent, similar E D values were obtained on the array as compared to levels outside the array in the nucleus. Also, the effects on E D of tamoxifen alone or in combination with forskolin on the PRL array were comparable with those detected outside the array ( Figure 3E ). These results indicated that the interaction detected between ERa and SRC-1 FL on a genuine ER binding domain, the PRL array, reflects the interaction at other sites in the nucleus.
Phosphorylation of serine-305 of ERa by PKA enables recruitment of RNA polymerase II to the PRL transcription locus, enhancing transcription under tamoxifen conditions Genuine tamoxifen resistance would imply that the effect of PKA-induced phosphorylation of ERa-S305 on the positioning of SRC-1 and ERa following exposure to tamoxifen would lead to tamoxifen-mediated transactivation of ERa, with recruitment of RNA polymerase II to the ERa/SRC-1 complex as a hallmark. Therefore, we investigated the RNA polymerase II recruitment in the PRL array containing cells that were transfected with ERa-CFP and SRC-1 FL -YFP, and examined colocalization of ERa and SRC-1 with RNA polymerase II on the PRL array. Approximately one-half of the cells expressing both ERa wt -CFP and SRC-1 FL -YFP showed colocalization with RNA polymerase II on the PRL array under conditions of CTS and E2 ( Figure 4A , and quantified in Figure 4B ). The PRL Figure 4 PKA-mediated phosphorylation of S305 of ERa is responsible for RNA polymerase II recruitment on the PRL array and for enhanced transcription of a hormone-responsive reporter gene under conditions of tamoxifen. (A) Staining for RNA polymerase II was performed on PRL array containing HeLa cells that were transfected with ERa wt -CFP or ERa S305A -CFP and SRC1 FL -YFP and cultured in hormone-depleted (CTS) medium. Where indicated, they were pretreated with 10 mM forskolin. Subsequently cells were treated with 1 mM Estradiol (E2) or 1 mM 4 0 OHtamoxifen for 2 h and then fixed and stained for RNA polymerase II. Arrowheads indicate the PRL array that was analyzed for RNA polymerase II staining. (B) Quantification of the RNA polymerase II signals on the PRL array under conditions as described in Figure 6A . Quantifications are from three independent experiments, n440 cells each. Bars indicate standard deviations. (C) PKA-mediated phosphorylation of S305 on ERa enhances transcription of the PRL array under conditions of tamoxifen. QPCR was performed on PRL array containing HeLa cells, transfected with ERa wt -CFP or ERa S305A -CFP, which were treated with 1 mM tamoxifen or left untreated (CTS). Sixteen hours before analysis, 100 mM 8-BrcAMP was added, where indicated. mRNA levels were measured as described in Materials and methods, and related to CTS values, which was set to 1. Bars indicate standard deviation from two independent experiments. RNA FISH of the hormone-responsive DsRed2 reporter gene behind the PRL-based promoter in PRL-HeLa transfected with ERa wt -CFP or ERa S305A -CFP. Two hours before analysis, cells were treated with forskolin, where indicated, and subsequently with 1 mM 4 0 OH-tamoxifen. Signal intensity of the FISH DsRed2, as visualized by Alexa-546, is shown. Bars indicate standard deviation from two independent experiments. array did show a more 'open', decondensed structure due to Estradiol (E2) when compared to hormone-depleted conditions (CTS). This open chromatin structure was previously reported to be tightly linked with increased transcriptional activity (Sharp et al, 2006) . In our experiments, activation of PKA by forskolin did not affect colocalization of the three proteins (ERa, SRC-1 and RNA polymerase II) under conditions of CTS and E2. As reported previously (Sharp et al, 2006) , tamoxifen-treated cells showed a more condensed PRL array, on which both ERa and SRC-1, but no RNA polymerase II was recruited ( Figure 4A ). Strikingly, activation of PKA under tamoxifen conditions now resulted in recruitment of RNA polymerase II to the array, indicating that PKA activation influenced the orientation between ERa and SRC-1, such that RNA polymerase II recruitment to the PRL array is facilitated under tamoxifen conditions. The S305A mutant of ERa did not result in RNA polymerase II recruitment under identical conditions ( Figure 4A and Supplementary Figure  S5 ). This indicates that RNA polymerase II recruitment to the ERa complex in tamoxifen-treated cells requires phosphorylation of ERa S305 by PKA.
To directly investigate whether these events resulted in enhanced transcription, we measured transcription of the integrated DsRed2 reporter gene that is under control of the ER-responsive elements on the PRL array (Sharp et al, 2006) by quantitative RT-PCR and RNA FISH as described in Materials and methods ( Figure 4C ). PKA activation led in tamoxifen-treated cells transfected with ERa wt to a two-fold increase in transcription of the DsRed2 gene, as compared to tamoxifen alone, whereas no such effect was observed in cells transfected with ERa S305A . Tamoxifen exposure resulted in a similar PKA-induced increase in DsRed2 transcripts, which was specifically associated with the PRL array, as shown by RNA FISH in cells transfected with wild-type ERa, but not in ERa S305A -transfected cells.
Our results indicated that tamoxifen resistance is due to a change in the orientation between ERa and SRC-1, which was dependent on PKA-mediated phosphorylation of ERa S305 . This reorientation between the C-termini of ERa and SRC-1 FL induced RNA polymerase II recruitment, resulting in enhanced transcription.
Interaction between ERa and AF-1 binding domain of SRC-1 is maintained under tamoxifen conditions
Which domain outside the AF-2 binding domain on SRC-1 is responsible for the sustained interaction between ERa and the full-length SRC-1 following tamoxifen exposure, as was observed in the FRET experiments? To study this, we determined colocalization of ERa-CFP, RNA polymerase II and an AF-1 binding domain of SRC-1 (Onate et al, 1998; Webb et al, 1998; Glass and Rosenfeld, 2000; Metivier et al, 2001) . We reduced the SRC-1 fragment, which was previously reported to interact with the AF-1 of ERa by others (Metivier et al, 2001) , to a SRC-1 1051À1240 fragment still showing interaction with the AF-1 of ERa (data not shown). We observed colocalization of ERa-CFP and SRC-1 1051À1240 -YFP on the PRL array under conditions of CTS, E2 and tamoxifen, and also under tamoxifen conditions after PKA activation ( Figure 5 ). No RNA polymerase II was recruited under these conditions, which is explained by a dominant-negative function of the SRC-1 1051À1240 mutant. This may also be indicated by the condensed shape of the PRL array in cells, also in the presence of E2, which is representative for the lack of transcriptional activity (Sharp et al, 2006) .
The condensed shape of the PRL array in the presence of E2 when ERa was coexpressed with the dominant-negative SRC-1 1051À1240 mutant also indicated that other endogenous SRCs do not compensate or otherwise influence our measurements. The combined results indicated that PKA-mediated phosphorylation of ERa-S305 in the presence of tamoxifen resulted in a reorientation between the C-termini of ERa and SRC-1, whereas the binding is sustained via an interaction between ERa and the AF-1 binding domain of SRC-1 in SRC-1 1051À1240 . This altered orientation between the C-termini of ERa and SRC-1 resulted in RNA polymerase II recruitment and transcriptional activity under tamoxifen conditions, and explains how PKA activation can result in tamoxifen resistance.
Discussion
Regulated gene expression is achieved through the coordinated assembly of transcription factors, cofactors and the basal transcription machinery to transcription start sites, and demands a spatio-temporal coordination of interactions between these components. Traditional models of transcription tend to be static and depend on overall interactions measured by various kinds of binding assays, whereas the generation of transcription factor complexes requires a fine-tuned recruitment of components depending mainly on affinity of interfaces. The present study shows that the orientation of a tamoxifen-bound ERa transcription factor towards its coactivator SRC-1 is altered by PKA-mediated phosphorylation of S305 in the hinge region of ERa. This reorientation is responsible for RNA polymerase II recruitment and ER-dependent transcription in the presence of tamoxifen, as is illustrated in Figure 6 . This reorientation was observed by a direct intermolecular FRET in living cells (Figures 2 and 3 ) that measures distance and/or orientation between the two fluorescently tagged proteins. Other methods, such as M2H and FRAP (Figure 1) , measure protein-protein interactions, respectively, interactions with more static complexes and stability of these complexes. These M2H and FRAP approaches did not show an effect of PKA on overall binding between ERa and SRC-1 under tamoxifen conditions. However, this PKA-mediated reorientation of ERa leads to recruitment of RNA polymerase II and enhanced transcription from a hormone-responsive reporter gene (Figure 4) . Our data indicate that the orientation of interfaces between ERa and SRC-1 in the transcription complex is crucial for efficacy of transcription and provides a molecular mechanism for tamoxifen resistance.
We found no differences in the FRET efficiency resulting from the interactions of ERa with SRC-1 on the PRL array, as compared to FRET signals scattered in the nucleoplasm ( Figure 3E ). This indicates that ERa/SRC-1 interactions can be visualized throughout the nucleus, and that their relative orientations are unaltered by DNA binding. Possibly such complexes are not assembling at the transcription start sites, but exist as preformed complexes in the nucleoplasm, as also suggested by others (Zheng et al, 2005) . At present, it is technically impossible to determine if the nucleoplasmic hot spots are sites of active genes containing EREs, or nonpromoter-associated EREs.
The PKA-mediated phosphorylation of S305 in the hinge region of ERa is responsible for a reorientation of the Cterminus of ERa under tamoxifen conditions, which we measured by FRET using C-terminally tagged ERa-CFP and SRC-1-YFP constructs (Figures 2 and 3) . This reorientation alters the interaction between the C-termini of ERa and SRC-1 and depends on prolonged association via AF-1 of ERa ( Figure 5 ). This was inferred from the absence of interactions between the AF-2 binding SRC-1 fragment and ERa under tamoxifen conditions. In addition, this AF-2/SRC-1 interaction was also not induced by PKA activation ( Figures 1B, C  and 2 ), whereas the AF-1 binding SRC-1 fragment did interact with ERa under tamoxifen conditions ( Figure 5 ). Our results thus support previous findings that AF-1 binding is a prerequisite for resistance to tamoxifen (Glaros et al, 2006) , whereas functional synergy between AF-1 and AF-2 enhances SRC-1 recruitment and subsequent transcription (Metivier et al, 2001) . Since the PKA effect on orientation is visualized only in the presence of tamoxifen, and not under conditions of CTS, the AF-1 domain should be regarded as a ligand dependent (in this case tamoxifen-dependent) transactivation domain that requires PKA activation. The AF-2 binding fragment of the SRC-1 construct that we used in this study as an AF-2 probe, encompasses aa 623-711 and contains two LXXLL motives that interact with the cofactor binding pocket in the AF-2 of the ERa-LBD (Llopis et al, 2000) . The results with this AF-2 probe in our M2H and FRAP experiments indicate that it binds to ERa under conditions of E2 and CTS, but not in the presence of tamoxifen. This binding was not influenced by activation of PKA. The full-length SRC-1 FL , however, binds to ERa under all three conditions when measured by M2H and FRAP, and was also observed on the PRL array in colocalization studies (Sharp et al, 2006) and FRET (Figure 3) , as was also the case for the AF-1 binding SRC-1 1051À1240 fragment ( Figure 5 ). This binding is also not affected by PKA activation. Since SRC-1 FL binds to both AF-1 and AF-2 domains of ERa (Metivier et al, 2001) , and SRC-623À711 only to the AF-2 domain, our results indicate that the AF-1 functional core in ERa, which is positioned at the start of the B-domain (aa 39-45 of ERa) (Metivier et al, 2001) , is involved in the interaction between ERa and the 1051-1240 domain of SRC-1 in tamoxifen-treated cells. Indeed, an SRC-1 mutant, previously described to bind the AF-1 region of ER (Metivier et al, 2001) , was still capable of interacting with ER on the PRL array in the presence of tamoxifen ( Figure 5 ). Interaction between this AF-1 helical core and SRC-1 has been reported to be essential for ERa activity in the presence of tamoxifen (Glaros et al, 2006) , and is most likely involved in the PKA-mediated reorientation between ERa and SRC-1 that we observed in our experiments under tamoxifen conditions. The outcome of our M2H and FRAP experiments, that measure interactions between ERa and SRC-1 FL molecules, was not influenced by tamoxifen. The outcome of the FRET experiments that measure distance and orientation between them was, however, affected by tamoxifen. From these results, we concluded that the orientation between the C-termini of ERa and SRC-1 FL , rather than the interaction between the two proteins, was altered by tamoxifen. This tamoxifen-associated alteration is prevented by phosphorylation of S305 of ERa by PKA, which stabilizes in the presence of tamoxifen the orientation towards SRC-1 (Figure 3 and Supplementary Figure S4 ). These findings led to a model where PKA-mediated phosphorylation of S305 results in a conformational state of ERa, by which the orientation between ERa and SRC-1 facilitates recruitment of RNA polymerase II under conditions of tamoxifen. The effect of PKA on the conformation of ERa involves most likely the reorientation between the N-and C-termini of ERa that we have observed by intramolecular FRET, as has been reported before (Michalides et al, 2004) . This intramolecular change was dependent on PKA-mediated phosphorylation of S305 and resulted in enhanced transactivation of ERa-and tamoxifen-dependent proliferation after PKA activation. In tamoxifen-resistant ER-positive patients, PKA activity was found increased, underlining the clinical relevance of these findings. The results of the present study strongly indicate that the change of ERa conformation upon PKA activation results in a permissive orientation between ERa and SRC-1 that facilitates transcription under tamoxifen conditions. Besides the phosphorylation of direct target sites in ERa, the phosphorylation of SRC-1 (Rowan et al, 2000b) and reduced association between ERa and transcriptional corepressors NCoR and SMRT (Wagner et al, 1998) may contribute to PKA-mediated resistance to anti-estrogens. Since the PKA-induced reorientation, the RNA polymerase II recruitment and enhanced transcription were not observed when the ERa S305A mutant was used ( Figure 3D and Supplementary Figure S3) , we conclude that phosphorylation of S305 by PKA is the main target for PKA-induced tamoxifen resistance that may still act in conjunction with phosphorylation of SRC-1 and NCoR/SMRT.
The reorientation of the C-terminus of tamoxifen-bound ERa toward SRC-1 that is induced by either PKA-or PAK-1-mediated phosphorylation of S305 in the hinge region of ERa, provides a unique model for resistance to tamoxifen. It demonstrates that the effect of interacting agents can be nullified by activation of other signaling pathways, adding to the complexity of estrogen-mediated transcriptional events and complicating interfering strategies. This mechanism also provides a framework for selection and development of agents that are insensitive to these modifications on ERa, and contributes to identification of conditions for tamoxifen resistance in breast cancer patients.
Materials and methods
Plasmids, cell culture and transfections
Human osteosarcoma U2OS, MCF7 and HeLa cells were cultured in DMEM medium in the presence of 10% FCS and standard antibiotics. Cells containing ERa were cultured in phenol red-free DMEM medium containing 5% CTS (Hyclone), 48 h before analysis.
For characterization of the ERa-S305 phosphorylation of ERa by PKA, U2OS cells were transfected with the YFP-ERa-CFP construct or the S305A variant thereof (Michalides et al, 2004) , treated with 100 mM 8-Br-cAMP (Sigma) and analyzed by Western blotting using antibodies against GFP (van Ham et al, 1997) , tubulin (Sigma) or phospho-S305-ERa (Upstate, USA). Cloning strategies are described in the Supplementary data. Figure 6 A model of the molecular mechanism of the PKA-or PAK1-induced tamoxifen resistance. In the presence of tamoxifen, SRC-1 binds to the AF-1 but not to the AF-2 domain of ERa. Phosphorylation of ERa-S305 by PKA results in an altered orientation between the C-termini of ERa and SRC-1, which differs from the orientation under conditions of CTS. This ERa-S305-specific phosphorylation by PKA leads to recruitment of RNA polymerase II and to elevated transcription in the presence of tamoxifen.
M2H assay U2OS cells were cultured in 12-well plates, 96 h before analysis. Twenty-four hours later, cells were transfected using PEI (polyethylenimine, MW 25 kDa (Polysciences Inc.)) (Boussif et al, 1995) with TA-ERa wt or TA-ERa S305A (0.5 mg), DBD-SRC-1-YFP (full length or aa 623-711) (0.5 mg), GAL4-responsive Luciferase reporter construct (0.5 mg) and ER-insensitive Renilla luciferase construct (1 ng) as control for transfection efficiency (Michalides et al, 2004) . Four hours after transfection, medium was replaced with Dulbecco's medium without phenol red, supplemented with 5% CTS (Hyclone) and cultured in the absence or presence of E2, ICI 182,780 (Tocris) or 4 0 OH-tamoxifen (Sigma), at a final concentration of 1 mM. Twenty-four hours before analysis, medium with (anti-) estrogens was replaced and 8-Br-cAMP (Sigma) was added where indicated, at a final concentration of 100 mM. Luciferase activity was determined as described previously (Bindels et al, 2002) .
FRAP is described in the Supplementary data.
FRET imaging by sensitized emission
HeLa cells were cultured on coverslips for 48 h before imaging. Twenty-four hours before imaging, cells were transfected with the constructs indicated, and medium was replaced with Dulbecco's medium without phenol red, supplemented with CTS. Mel-JuSo cells, stably transfected with pcDNA3 constructs containing only CFP or YFP, were included to the culture for leak-through corrections and internal controls. Coverslips were placed in 2 ml bicarbonate/Hepes-buffered saline and analyzed in a heated tissue culture chamber at 371C under 5% CO 2 . Where indicated, forskolin was added at a final concentration of 10 mM for 15 min. FRET between CFP and YFP molecules was determined by calculating the sensitized emission (the YFP emission upon CFP excitation) using separately acquired donor and acceptor images, as described previously (Zwart et al, 2005) . In short, images were acquired on a TCS-SP2 confocal microscope (Leica). Three images were collected: CFP (excited at 430 nm and detected between 470 and 490 nm), indirect YFP (excited at 430 nm and detected between 528 and 603 nm) and direct YFP (excited at 514 nm and detected between 528 and 603 nm). Because of considerable overlap of CFP and YFP spectra, YFP emission was corrected for leak-through of CFP emission, and for direct excitation of YFP during CFP excitation. FRET was calculated using correction factors obtained from cells expressing either CFP or YFP alone, which were included for every image, as described before (van Rheenen et al, 2004) . Then the apparent E D was calculated by relating the FRET to the total emission of the donor cell, after which the E D image was overlaid with a false color look up table. Using these methods, differences in FRET efficiency can be measured with an accuracy of 0.5% (Zwart et al, 2005) . For graphic representation, the E D was calculated for each pixel from the raw data files of the represented cell, and was exported to Microsoft Excel. Here, the amount of pixels was related to the corresponding E D , and plotted as a histogram (Zwart et al, 2005) .
RNA polymerase II recruitment assay
For CLSM analysis, prolactin promoter/enhancer (PRL) array containing HeLa cells (Sharp et al, 2006) were cultured in Dulbecco's medium containing CTS and were transfected with ERa wt -CFP or ERa S305A -CFP and SRC-1 FL -YFP or the 1051-1240 truncation mutant thereof, using PEI. After 4 h, the medium was replaced with Dulbecco's medium without phenol red, supplemented with 5% CTS. Cells were cultured in CTS only or supplemented with 10 mM forskolin for 15 min. Subsequently, cells were treated for 2 h with 1 mM Estradiol, 1 mM 4 0 OH-tamoxifen or left untreated, thereafter fixed with 3.7% formaldehyde in PBS and subsequently stained with anti-RNA polymerase II antibody 8WG16 (Covanche Research Products Inc.) and secondary antibodies conjugated to Alexa 633 (Molecular Probes, Leiden, The Netherlands). Images were obtained with a Leica TCS SP2 System equipped with a Â 63 oil-immersion objective. CFP was excited at 458 nm, and emission measured at 460-500 nm. YFP was excited at 514 nm, and emission measured at 528-600 nm. Alexa 633 was excited at 633 nm, and emission measured at 645-720 nm.
Quantitative RT-PCR and RNA FISH Prolactin promoter/enhancer (PRLÀ) array containing HeLa cells (Sharp et al, 2006) were transfected with ERa wt -CFP or ERa S305A -CFP using electroporation, and subsequently cultured in Dulbecco's medium containing CTS. Immediately after seeding the cells, 1 mM 4 0 OH-tamoxifen was added or the cells were left untreated. After 6 h, 8-Br-cAMP was added, where indicated, at a final concentration of 100 mM. After 16 h, cells were lysed and RNA was extracted using Trizol (Invitrogen), according to the manufacturer's protocol. RNA was reverse transcribed using SuperScript(tm) III Reverse Transcriptase (Invitrogen), on which QPCR was performed using CYBR Green (Applied Biosystems), according to the manufacturer's protocols. The DsRed2 cDNA was amplified with the forward primer 5 0 CCAGTTCCAGTACGGCTCCA and the reverse primer 5 0 GCCGTCCTCGAAGTTCATCA. As a control, the observed DsRed2 signal was related to b-actin RNA levels, using a forward primer 5 0 CCTGGCACCCAGCACAAT and reverse primer 5 0 GGGCCGGACTCGTCATACT. RNA FISH was performed as described previously (Sharp et al, 2006) . PRL array containing HeLa cells were transfected with either CFP-ERa wt or CFP-ERa S305A and treated 2 h before analysis with 10 mM forskolin for 15 min, followed by treatment with 1 mM 4 0 OHtamoxifen, or treated with 4 0 OH-tamoxifen only. The cells were stained with an antibody against ERa (Clone 60C, Upstate), and RNA FISH for DsRed2 transcripts was performed as described previously (Sharp et al, 2006) . Informative arrays were analyzed for the Alexa-546 signal intensity of DsRed2 transcripts.
Supplementary data
Supplementary data are available at The EMBO Journal Online (http://www.embojournal.org).
